6-N-linked heterocycle-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists
申请人:Eli Lilly and Company
公开号:US07981882B2
公开(公告)日:2011-07-19
The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R6 is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification.
6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
申请人:ELI LILLY AND COMPANY
公开号:EP1924578B1
公开(公告)日:2013-11-06
US7981882B2
申请人:——
公开号:US7981882B2
公开(公告)日:2011-07-19
[EN] 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS<br/>[FR] 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES SUBSTITUEES PAR UN HETEROCYCLE A LIAISON 6-N EN TANT QU'AGONISTES DE RECEPTEUR 5-HT2C
申请人:LILLY CO ELI
公开号:WO2007028132A2
公开(公告)日:2007-03-08
[EN] The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H- benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R6 is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification. [FR] La présente invention propose des 2,3,4,5-tétrahydro-1H-benzo[d]azépines 6-substituées de formule I en tant qu'agonistes sélectifs de récepteur 5-HT2C pour le traitement de troubles associés à 5-HT2C comprenant l'obésité, les troubles obsessionnels compulsifs, la dépression, et l'anxiété : Formule (I) dans laquelle : R6 est choisi dans le groupe constitué de (a, b, c, d, e) et les autres substituants sont comme définis dans la spécification.
6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists
申请人:Briner Karin
公开号:US20080214520A1
公开(公告)日:2008-09-04
The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT
2C
receptor agonists for the treatment of 5-HT
2C
associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R
6
is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification.